Author profile
Elizabeth is responsible for technical and strategic product development, leading a cross-functional R&D and product development team and key strategic external partners.
This includes the development of the proprietary DARE-IDDS (Intelligent Drug Delivery System) platform technology, which is designed to provide programmable, precise, long-term drug delivery from a subcutaneously implanted device. Elizabeth joined Daré as part of the acquisition of Microchips Biotech in November 2019. Throughout her career Elizabeth has developed and advanced novel products for numerous applications and therapeutic areas through clinical development, including bone substitute materials, pulmonary therapies, injectable sustained release products, and implantable drug delivery devices. During her 15-year tenure at Microchips Biotech, she advanced the legacy company to its First-In-Human clinical study with parathyroid hormone, a treatment for osteoporosis. Elizabeth also has significant preclinical testing experience and has worked closely with clinical, regulatory affairs, and marketing as a technical expert to advance complex product development and incorporate the end user perspective. Elizabeth has also held leadership and technical positions at BD, Lantheus Medical Imaging, Epic Therapeutics (a wholly owned subsidiary of Baxter Healthcare), and Etex Corporation. She has more than 26 years of experience in drug delivery science and product development of combination products and medical devices. Elizabeth graduated from Wellesley College with a degree in Chemistry.
DDF (Drug Delivery Formulation) focuses on bringing innovative solutions to the greatest challenges in pharmaceuticals, biologics and device development. Lunch and learn roundtable discussion: One implantable platform, 10-year life. A new era in drug delivery....